Stable Cell Line Construction Services

Inquiry

As a preclinical CRO specializing in oncology, Alfa Cytology provides professional stable cell line construction services designed to deliver high-quality, reproducible cell models for your research programs. From gene overexpression to reporter gene systems, our scientific team offers full-process customized services, from vector design to monoclonal screening, tailored to your specific research objectives, accelerating your oncology drug discovery and development.

Introduction to Stable Cell Line Construction

Stable cell lines are cell models generated by the stable integration of exogenous genes, whether target genes or reporter genes, into the host cell genome, enabling long-term, sustained expression. Unlike transient expression systems, stable cell lines ensure the continuous transmission of exogenous genes to daughter cells during cell division, providing reliable and reproducible experimental tools for long-term studies and drug development. The construction of stable cell lines typically involves multiple critical steps, including gene synthesis, vector construction, transfection, monoclonal selection, expansion, and quality validation. Throughout the entire workflow, rigorous quality control is essential to ensure the stability, homogeneity, and performance of the resulting cell lines.

Stable cell lines are widely used across a broad range of research applications:

Recombinant Protein and Antibody Production: Providing high-expressing, stable production cell lines for biopharmaceutical development.
Drug Target Discovery and Validation: Enabling the screening and validation of potential targets through overexpression or reporter gene systems.
Signal Transduction Research: Facilitating real-time monitoring of pathway activation using reporter gene systems.
Gain-of-Function Studies: Investigating the biological functions of target genes via stable overexpression.

Fig. 1 Stable cell line generation process. Fig. 1 A workflow of the stable cell line generation process. (Srila W, et al.; 2023)

Our Services

Stable cell line construction is a core technology platform that integrates exogenous genes or regulatory elements into the host cell genome to achieve long-term, stable expression. Alfa Cytology provides comprehensive customized services covering the entire workflow—from gene synthesis, vector construction, cell transfection, monoclonal screening, and stability validation to cell banking—ensuring that every delivered cell line exhibits high homogeneity, stability, and complete documentation support to meet the needs at all stages from early research to IND filing.

Monoclonal Stable Cell Line Construction

Derived from a single cell isolated via limiting dilution or single-cell sorting, monoclonal cell lines exhibit high homogeneity and stable expression levels, making them the preferred choice for high-precision research and biopharmaceutical manufacturing.

Polyclonal Stable Cell Line Construction

A mixed cell population obtained through direct drug selection of transfected cells. This approach offers rapid turnaround and cost-effectiveness, making it ideal for preliminary functional screening and expression assessment.

Overexpression Cell Line Construction

Target genes are stably integrated into the host cell genome to achieve high-level, sustained protein expression. This service is widely applied in gain-of-function studies, recombinant protein production, and ADC target development.

Reporter Cell Line Construction

Reporter systems (e.g., Luciferase, GFP) are stably integrated into host cells to enable real-time, quantitative monitoring of specific signaling pathways or gene expression activities. These cell lines are widely used in high-throughput drug screening, signal transduction research, and immuno-oncology evaluation.

Service Details

Service Step	Service Details	Turnaround Time
Gene Synthesis and Vector Construction	Full-length synthesis of target gene Expression vector construction (with selection markers) Sequence verification	2–3 weeks
Cell Transfection and Stable Pool Selection	Transfection of host cells (CHO/HEK293/client-specified cell lines) Antibiotic selection to enrich stably integrated cell populations Cryopreservation of early-passage stocks	3–4 weeks
Single-Cell Isolation	Limiting dilution or FACS-based single-cell sorting Single-cell seeding into 96-well plates Imaging documentation to confirm monoclonality	1 week
Clone Screening and Expansion	Microscopic observation and growth monitoring Multiple rounds of screening by qPCR/Western blot/flow cytometry Stepwise scale-up (96→24→6-well→shake flask) Candidate clones narrowed down to 2–3 clones	6–10 weeks
Stability Testing	Continuous passaging for ≥20 generations Sampling and testing at P5/P10/P15/P20 Assessment of expression level and cell growth performance Expression consistency verification (CV ≤ 30%)	8–12 weeks
Cell Banking	Master Cell Bank (MCB, ≥20 vials) Working Cell Bank (WCB, ≥10 vials) ≥1×10⁶ cells per vial, cryopreserved in vapor-phase liquid nitrogen	1–2 weeks
Quality Release and Delivery	STR authentication and mycoplasma testing Target gene expression verification Copy number analysis and sequencing validation Complete COA report and cryopreserved cell delivery	2–3 weeks

Technology Platform

Gene Delivery Systems

Lentivirus, AAV, and transposon platforms

Gene Editing Technology

CRISPR/Cas9 platform enabling highly efficient and precise gene editing

Monoclonal Screening

Limiting dilution, FACS-based single-cell sorting

Quality Validation

Sequencing, expression, bioactivity, STR, and mycoplasma testing

Application

By Therapeutic Modality

Therapeutic Modality	Required Cell Line Types	Representative Cell Lines
ADC Drug Development	Target antigen overexpression cell lines	HER2⁺ SK-BR-3, TROP2⁺ MDA-MB-468
CAR-T Cell Therapy	Target antigen overexpression cell lines + Luc labeling	CD19⁺ Raji-Luc, BCMA⁺ MM.1S-Luc
Immune Checkpoint Inhibitors	Reporter cell lines (PD-L1/NFAT)	PD-L1⁺ CHO-K1, NFAT-Luc Jurkat
Bispecific Antibodies	Target antigen overexpression cell lines + NFAT reporter	CD3/CD19⁺ Raji + NFAT Jurkat
ADCC/ADCP/CDC	Target antigen overexpression cell lines + FcγR reporter	HER2⁺ SK-BR-3 + FcγRIIIa Jurkat
Small Molecule Targeted Therapy	Target overexpression cell lines, drug-resistant cell lines	EGFR⁺ A431, EGFR-T790M⁺ Ba/F3
PROTAC/Molecular Glues	Target protein overexpression cell lines	BRD4⁺ HCT116, AR⁺ VCaP
Oncolytic Viruses	Viral receptor overexpression cell lines	CAR⁺A549, CD46⁺ HCT116
Gene Therapy/AAV	Reporter gene overexpression cell lines	Luc⁺ HeLa, LacZ⁺ HEK293
Cancer Vaccines	Target antigen overexpression cell lines	NY-ESO-1⁺ A375, MAGE-A3⁺ SK-MEL-37

By Tumor Type

Tumor Type	Stable Cell Lines	Modification Type
Breast Cancer	SK-BR-3 HER2⁺; MDA-MB-231 Luc⁺; BT-474 HER2⁺	Overexpression; Luciferase labeling; Overexpression
Lung Cancer	A549 Luc⁺; H1975 EGFR-T790M⁺; H460 Luc⁺	Luciferase labeling; Resistant mutant overexpression; Luciferase labeling
Colorectal Cancer	HCT116 Luc⁺; HCT116 KRAS-G12C⁺	Luciferase labeling; Mutant gene overexpression
Stomach Cancer	NCI-N87 HER2⁺; MKN-45 Luc⁺	Overexpression; Luciferase labeling
Pancreatic Cancer	PANC-1 Luc⁺; AsPC-1 KRAS-G12D⁺	Luciferase labeling; Mutant gene overexpression
Liver Cancer	HepG2 Luc⁺; HCCLM3 Luc⁺	Luciferase labeling; Luciferase labeling
Ovarian Cancer	OVCAR-3 Luc⁺; SK-OV-3 HER2⁺	Luciferase labeling; Overexpression
Prostate Cancer	LNCaP AR⁺; PC-3 Luc⁺	Overexpression; Luciferase labeling
Leukemia	K562 Luc⁺; NALM6 Luc⁺	Luciferase labeling; Luciferase labeling
Lymphoma	Raji Luc⁺; Raji CD19⁺	Luciferase labeling; Overexpression
Multiple Myeloma	MM.1S Luc⁺; MM.1S BCMA⁺	Luciferase labeling; Overexpression
Melanoma	A375 Luc⁺; SK-MEL-28 Luc⁺	Luciferase labeling; Luciferase labeling
Glioblastoma	U-87 MG Luc⁺	Luciferase labeling
Renal Cancer	786-O Luc⁺	Luciferase labeling
Bladder Cancer	T24 Luc⁺; 5637 Nectin-4⁺	Luciferase labeling; Overexpression

Leveraging our mature stable cell line construction platform, Alfa Cytology delivers customized solutions, from overexpression and reporter systems to positive marker cell lines, supporting ADC, CAR-T, immune checkpoint inhibitors, and other therapeutic modalities. Whether you are at target validation, in vitro efficacy screening, or IND-enabling studies, our rigorous processes and comprehensive quality control systems back your project at every stage. Please don't hesitate to contact us to learn how our expertise can accelerate your oncology research.

References

Srila W, et al. Glutamine synthetase (GS) knockout (KO) using CRISPR/Cpf1 diversely enhances selection efficiency of CHO cells expressing therapeutic antibodies. Sci Rep. 2023;13(1):10473.
Zhou YF, et al. Construction of A375·S2 Melanoma Cell Line with High Sensibility to IL-1 by Overexpressing IL-1 Receptor. Indian J Microbiol. 2022;62(4):550-557.

For research use only.

Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.